Indications : התוויות

4.1     Therapeutic indications
Breast cancer
• Docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
• Docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.
• Docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.



• Docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors over-express HER2 and who previously have not received chemotherapy for metastatic disease.
• Docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.
• Doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (AC- TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high-risk node-negative, breast cancer.
• Docetaxel in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high-risk node-negative, breast cancer.
Non-small cell lung cancer: Docetaxel is indicated for the treatment of patients with advanced non- small cell lung carcinoma.

Ovarian cancer: Docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy.

Prostate cancer: Docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.

Esophageal cancer: Docetaxel for the treatment of esophageal cancer.

Gastric cancer: Docetaxel for the treatment of advanced gastric cancer.
Head and neck (SCCHN):
• Docetaxel as monotherapy in the treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after failure of a previous chemotherapy regimen.
• Docetaxel in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.